$BIOCQ
Biocept Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020053979 Filed on November 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q4
Revenue $6.586M $917.5K $1.784M
YoY Change 330.67% -22.99% 107.53%
Cost Of Revenue $5.859M $2.520M $2.870M
YoY Change 106.84% -5.74% 17.85%
Gross Profit $726.8K -$1.600M -$1.090M
YoY Change -155.76% 7.96% -30.83%
Gross Profit Margin 11.03% -174.39% -61.11%
Selling, General & Admin $4.458M $3.240M $3.400M
YoY Change 40.95% -1.55% 10.62%
% of Gross Profit 613.37%
Research & Development $1.088M $1.590M $1.160M
YoY Change -6.51% 38.47% -10.0%
% of Gross Profit 149.67%
Depreciation & Amortization $360.0K $240.0K $240.0K
YoY Change 49.87% 4.87% 9.09%
% of Gross Profit 49.53%
Operating Expenses $5.546M $4.830M $4.560M
YoY Change 28.18% 8.8% 4.53%
Operating Profit -$4.819M -$6.430M -$5.650M
YoY Change -14.4% 8.59% -4.85%
Interest Expense $59.55K -$60.00K -$60.00K
YoY Change -4.0% -194.38% -25.0%
% of Operating Profit
Other Income/Expense, Net -$59.55K $0.00 $0.00
YoY Change -4.0% -100.0% -100.0%
Pretax Income -$4.878M -$6.490M -$5.710M
YoY Change -14.29% -16.97% -4.99%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.878M -$6.489M -$5.710M
YoY Change -14.29% -16.97% -5.06%
Net Earnings / Revenue -74.07% -707.3% -320.11%
Basic Earnings Per Share -$0.37 -$0.20
Diluted Earnings Per Share -$0.37 -$510.2K -$0.20
COMMON SHARES
Basic Shares Outstanding 13.33M 29.13M
Diluted Shares Outstanding 13.33M 29.13M

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.86M $24.05M $9.300M
YoY Change 157.8% 91.02% 171.93%
Cash & Equivalents $16.86M $24.05M $9.301M
Short-Term Investments
Other Short-Term Assets $700.0K $850.0K $300.0K
YoY Change 40.0% 44.07% -30.23%
Inventory $3.320M $970.0K $768.0K
Prepaid Expenses
Receivables $7.950M $3.180M $3.527M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $28.83M $29.06M $13.89M
YoY Change 172.36% 81.72% 131.12%
LONG-TERM ASSETS
Property, Plant & Equipment $3.980M $3.960M $1.504M
YoY Change 200.32% 224.83% -45.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.975M $3.960M $3.840M
YoY Change 0.99% 1.19% 40.18%
TOTAL ASSETS
Total Short-Term Assets $28.83M $29.06M $13.89M
Total Long-Term Assets $3.975M $3.960M $3.840M
Total Assets $32.80M $33.02M $17.73M
YoY Change 125.91% 65.89% 102.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.124M $1.930M $2.012M
YoY Change 233.91% -4.48% -1.37%
Accrued Expenses $2.623M $2.480M $1.980M
YoY Change 42.0% 66.35% 2.69%
Deferred Revenue
YoY Change
Short-Term Debt $210.0K $440.0K $0.00
YoY Change 61.54% 69.23%
Long-Term Debt Due $910.0K $790.0K $720.0K
YoY Change 16.67% 23.44% 12.5%
Total Short-Term Liabilities $10.11M $5.630M $5.559M
YoY Change 74.88% -3.3% 20.59%
LONG-TERM LIABILITIES
Long-Term Debt $1.340M $1.300M $970.0K
YoY Change 30.1% 51.16% -2.02%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $1.340M $1.300M $970.0K
YoY Change 29.81% 32.19% -11.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.11M $5.630M $5.559M
Total Long-Term Liabilities $1.340M $1.300M $970.0K
Total Liabilities $11.45M $6.930M $6.532M
YoY Change 68.02% 1.83% 14.44%
SHAREHOLDERS EQUITY
Retained Earnings -$265.4M -$245.7M
YoY Change 10.6% 11.46%
Common Stock $286.8M $256.9M
YoY Change 15.78% 14.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.35M $26.08M $11.20M
YoY Change
Total Liabilities & Shareholders Equity $32.80M $33.02M $17.73M
YoY Change 125.91% 65.89% 102.65%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q4
OPERATING ACTIVITIES
Net Income -$4.878M -$6.489M -$5.710M
YoY Change -14.29% -16.97% -5.06%
Depreciation, Depletion And Amortization $360.0K $240.0K $240.0K
YoY Change 49.87% 4.87% 9.09%
Cash From Operating Activities -$6.710M -$6.690M -$5.470M
YoY Change 19.61% -0.45% 0.92%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$20.00K -$440.0K
YoY Change -90.48% -66.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K -$20.00K -$440.0K
YoY Change -90.48% -66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -460.0K 9.270M 8.670M
YoY Change 100.0% 101.52% -7981.82%
NET CHANGE
Cash From Operating Activities -6.710M -6.690M -5.470M
Cash From Investing Activities -20.00K -20.00K -440.0K
Cash From Financing Activities -460.0K 9.270M 8.670M
Net Change In Cash -7.190M 2.560M 2.760M
YoY Change 18.84% -217.43% -149.91%
FREE CASH FLOW
Cash From Operating Activities -$6.710M -$6.690M -$5.470M
Capital Expenditures -$20.00K -$20.00K -$440.0K
Free Cash Flow -$6.690M -$6.670M -$5.030M
YoY Change 23.89% 0.15% -7.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2018691
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
21353297
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1337686
CY2020Q3 us-gaap Liabilities
Liabilities
11451338
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
286780895
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32804635
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2133
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13396570
CY2020Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
914671
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2133
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
724329
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1340
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13396570
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-265428938
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6123990
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2622722
CY2019Q4 us-gaap Assets
Assets
17732644
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1980204
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
842452
CY2020Q3 bioc Supplier Financings
SupplierFinancings
209312
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2011827
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
242957
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5558812
CY2020Q3 us-gaap Assets
Assets
32804635
bioc Warrant Inducement And Other Income Expenses
WarrantInducementAndOtherIncomeExpenses
-1831116
bioc Warrant Inducement And Other Income Expenses
WarrantInducementAndOtherIncomeExpenses
-2102109
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3042519
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
102459
CY2019Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
4748
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5916787
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14014084
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224641
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
4845722
CY2019Q2 bioc Adjustment To Additional Paid In Capital Warrant Inducement Expense
AdjustmentToAdditionalPaidInCapitalWarrantInducementExpense
1831116
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7816012
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
13099551
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
297669
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
142964
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2306708
CY2020Q1 bioc Adjustment To Additional Paid In Capital Warrant Inducement Expense
AdjustmentToAdditionalPaidInCapitalWarrantInducementExpense
2102109
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8341338
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
22730105
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
194236
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
72608
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6489303
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
26084943
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10113652
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
256917285
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8950160
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1163546
us-gaap Cost Of Revenue
CostOfRevenue
8105422
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
5859370
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
973189
CY2019Q4 us-gaap Liabilities
Liabilities
6532001
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1434481
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6839467
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17732644
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5473848
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3535116
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-59549
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4451628
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2133
us-gaap Net Income Loss
NetIncomeLoss
-19424558
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11200643
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Interest Expense
InterestExpense
62028
bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
2774
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1529262
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
11404929
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4818785
CY2020Q3 us-gaap Interest Expense
InterestExpense
59549
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
547
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245717189
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5473848
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4232867
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2133
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4878334
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1087741
us-gaap Operating Income Loss
OperatingIncomeLoss
-17405867
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3989133
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1700380
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3023337
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5058525
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1462335
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
7158996
us-gaap Costs And Expenses
CostsAndExpenses
21150691
us-gaap Costs And Expenses
CostsAndExpenses
26385135
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5629734
us-gaap Operating Income Loss
OperatingIncomeLoss
-17434975
us-gaap Interest Expense
InterestExpense
187575
us-gaap Interest Expense
InterestExpense
171891
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4878334
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
2832735
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3744824
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6586144
us-gaap Cost Of Revenue
CostOfRevenue
11323668
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19424558
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.47
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-62028
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5691762
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-5691762
bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
99743
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5691762
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2301819
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2301819
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.47
CY2020Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
8600000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2300000
CY2020Q1 us-gaap Share Price
SharePrice
4.10
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
166730
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
22388
us-gaap Profit Loss
ProfitLoss
-19424558
us-gaap Profit Loss
ProfitLoss
-19708975
us-gaap Depreciation And Amortization
DepreciationAndAmortization
691191
us-gaap Depreciation And Amortization
DepreciationAndAmortization
839794
bioc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
-113419
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
42430
bioc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
-105534
bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
-20277
bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
-57350
us-gaap Share Based Compensation
ShareBasedCompensation
624769
us-gaap Share Based Compensation
ShareBasedCompensation
503930
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
1831116
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
2102109
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1680
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1287334
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4427547
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
120241
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2605153
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-322299
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-165353
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-198400
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3853736
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
76932
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
642516
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17577368
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18684101
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
297877
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64331
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-297877
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64331
bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
16779772
bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
24193930
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2513172
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2401704
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2337298
bioc Proceeds From Exercise Of Overallotment Warrants
ProceedsFromExerciseOfOverallotmentWarrants
659958
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
378389
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
518190
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
260537
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
432435
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20991316
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26304967
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3116071
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7556535
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3423373
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9301406
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6539444
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16857941
us-gaap Interest Paid Net
InterestPaidNet
187574
us-gaap Interest Paid Net
InterestPaidNet
171891
bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
393000
bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
567000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
583000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
1073000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
25000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
67000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
32000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
173000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1846664
CY2020Q1 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
288
CY2020Q1 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
265000
CY2019Q1 us-gaap Share Price
SharePrice
22.50
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
595000
CY2019Q1 us-gaap Share Price
SharePrice
13.70
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
99000
CY2019Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
2000000
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.00
CY2018Q1 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
99000
CY2019Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
7500000
CY2019Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
CY2019Q1 bioc Class Of Warrant Or Rights Term
ClassOfWarrantOrRightsTerm
P5Y6M
CY2019Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
48
CY2020Q2 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
9600000
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On September 3, 2020, the Company filed an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a one-for-ten reverse stock split of the shares of common stock outstanding on September 4, 2020.
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-25100000
CY2020Q3 bioc Aggregate Net Interest Bearing Indebtedness
AggregateNetInterestBearingIndebtedness
2300000
CY2020Q3 bioc Aggregate Net Interest Bearing Indebtedness Due Within One Year
AggregateNetInterestBearingIndebtednessDueWithinOneYear
915000
CY2020Q3 bioc Other Non Interest Bearing Current Liabilities
OtherNonInterestBearingCurrentLiabilities
2800000
CY2020Q1 us-gaap Share Price
SharePrice
4.00
CY2020Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
6100000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1600000
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2230000
CY2020Q2 us-gaap Share Price
SharePrice
4.60
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.00
CY2019Q3 bioc Warrant Inducement Expense
WarrantInducementExpense
1800000
bioc Warrant Inducement Expense
WarrantInducementExpense
1800000
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1900000
bioc Warrant Inducement Expense
WarrantInducementExpense
2100000
CY2019Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
9.50
CY2019Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
6800000
CY2019Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
10.10
CY2019Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
6000000
CY2020Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
1900000
CY2020Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
2.80
CY2019Q1 bioc Adjusted Exercise Price Of Warrants
AdjustedExercisePriceOfWarrants
12.00
CY2019Q1 bioc Adjusted Exercise Price Of Warrants
AdjustedExercisePriceOfWarrants
12.50
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.495
CY2019Q1 bioc Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
2.70
CY2019Q1 bioc Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
2.70
CY2019Q1 bioc Estimated Fair Value Of Warrants Increased
EstimatedFairValueOfWarrantsIncreased
2.90
CY2019Q1 bioc Estimated Fair Value Of Warrants Increased
EstimatedFairValueOfWarrantsIncreased
3.00
CY2019Q1 bioc Class Of Warrants Or Rights Eligible For Price Modification
ClassOfWarrantsOrRightsEligibleForPriceModification
216725
CY2019Q1 bioc Class Of Warrants Or Rights Eligible For Price Modification
ClassOfWarrantsOrRightsEligibleForPriceModification
476000
CY2019Q1 bioc Warrant Inducement Expense
WarrantInducementExpense
60000
CY2019Q1 bioc Warrant Inducement Expense
WarrantInducementExpense
130000
CY2019Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2857538
CY2020Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2900943
CY2019Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
156987
CY2020Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
156987
CY2019Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
1552891
CY2020Q3 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
1552891
CY2019Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
570173
CY2020Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
570173
CY2019Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
625038
CY2020Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
907435
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5762627
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6088429
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4258297
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4481252
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
298855
CY2020Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
666735
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
622792
CY2020Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
857385
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
748742
CY2020Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
708281
CY2019Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
89562
CY2020Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
159775
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
220253
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
230546
CY2019Q1 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
149000
CY2019Q1 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q1 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
36
CY2019Q1 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
5013
CY2019Q1 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
180000
CY2019Q1 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2022-02
CY2019Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
100000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
540853
CY2019Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
62026
CY2020Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
56372
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
187574
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
164044
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
318005
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
357914
us-gaap Operating Lease Cost
OperatingLeaseCost
954015
CY2019Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
60
CY2019Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
1770
CY2019Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
2706
CY2019Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
130000
CY2019Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2023-05
CY2019Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
245000
CY2019Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
36
CY2019Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
8253
CY2019Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
297000
CY2019Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2022-08
CY2019Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
89000
CY2019Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
106000
CY2019Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2024-09
CY2020Q1 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
197000
CY2020Q1 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
11000
CY2020Q1 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q1 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q1 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
48
CY2020Q1 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
4532
CY2020Q1 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
14000
CY2020Q1 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2025-01
CY2020Q1 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2024-02
CY2020Q2 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
161000
CY2020Q2 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q2 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
60
CY2020Q2 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
3337
CY2020Q2 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
185000
CY2020Q2 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2025-03
CY2020Q2 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
334000
CY2020Q2 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q2 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
8966
CY2020Q2 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
469000
CY2020Q2 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2025-06
CY2020Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
143000
CY2020Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
60
CY2020Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
2772
CY2020Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
166000
CY2020Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2025-07
CY2020Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
226000
CY2020Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
16427
CY2020Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
261000
CY2020Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2025-07
CY2019Q4 bioc Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
2335717
CY2020Q3 bioc Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
2371157
CY2019Q4 bioc Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
1566781
CY2020Q3 bioc Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
1157628
CY2019Q4 bioc Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
973189
CY2020Q3 bioc Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
1337686
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
134472
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
266747
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
364401
us-gaap Operating Lease Cost
OperatingLeaseCost
993924
CY2019Q3 bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
514503
CY2020Q3 bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
681033
bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
1505990
bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
1698821
CY2020Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
280813
CY2020Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
915374
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
656100
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
515473
CY2020Q3 bioc Finance Lease Liability Payments Due Thereafter
FinanceLeaseLiabilityPaymentsDueThereafter
323474
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
32920
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
254356
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
250368
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
36.14
CY2020Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2691234
CY2020Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
438877
CY2020Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
2252357
CY2020Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Remainder Of Fiscal Year
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsRemainderOfFiscalYear
28630
CY2020Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due Next Twelve Months
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueNextTwelveMonths
95381
CY2020Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Two Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInTwoYears
73301
CY2020Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Three Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInThreeYears
57603
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.23
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.09
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
37.04
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
37.48
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M
CY2020Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due Thereafter
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueThereafter
45081
CY2020Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDue
299996
CY2020Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Net
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsNet
299996
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
244324
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
244324
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1367
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
242957
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
187574
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
164044
us-gaap Operating Lease Payments
OperatingLeasePayments
1067437
us-gaap Operating Lease Payments
OperatingLeasePayments
1099460
CY2020Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M4D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2M1D
CY2020Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1645
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.045
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1073000
bioc Share Based Compensation Arrangement By Share Based Payment Award Number Of Equity Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans
2
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
273406
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
13870
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.461
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.711
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M3D
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1846664
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1298702
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1298702
CY2019Q3 bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
35000
CY2020Q3 bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
29000
bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
82000
bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
111000

Files In Submission

Name View Source Status
0001564590-20-053979-index-headers.html Edgar Link pending
0001564590-20-053979-index.html Edgar Link pending
0001564590-20-053979.txt Edgar Link pending
0001564590-20-053979-xbrl.zip Edgar Link pending
bioc-10q_20200930.htm Edgar Link pending
bioc-20200930.xml Edgar Link completed
bioc-20200930.xsd Edgar Link pending
bioc-20200930_cal.xml Edgar Link unprocessable
bioc-20200930_def.xml Edgar Link unprocessable
bioc-20200930_lab.xml Edgar Link unprocessable
bioc-20200930_pre.xml Edgar Link unprocessable
bioc-ex101_127.htm Edgar Link pending
bioc-ex311_9.htm Edgar Link pending
bioc-ex312_7.htm Edgar Link pending
bioc-ex321_6.htm Edgar Link pending
bioc-ex322_8.htm Edgar Link pending
bioc-ex42_65.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g4kweeltrvrm000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending